辩论:重症患者选择间歇性血液透析还是连续性肾脏替代治疗应基于证据
该文讨论重症急性肾损伤(AKI)患者肾脏替代治疗(KRT)模式选择,指出比较间歇性血液透析(HD)与连续性肾脏替代治疗(CKRT)的随机对照试验(RCT)未显示任一技术在死亡率、血流动力学或肾功能恢复方面有实际获益,且这些RCT已超过15年,近期研究死亡率更低并显示部分患者无需KRT即可恢复。健康技术评估关于成本效果结论异质且矛盾,作者认为需在新RCT中重新评估,在结果出来前选择应主要基于各单位组织因素,在缺乏证据时不应否定任一模式。
要点
- 比较间歇性HD与CKRT的RCT未显示任一技术在死亡率、血流动力学或肾功能恢复方面有实际获益。
- 这些RCT已超过15年,近期研究死亡率更低且部分患者无需KRT即可恢复。
- 健康技术评估关于间歇性HD与CKRT成本效果的结论异质且矛盾。
核心结论
- 比较间歇性HD与CKRT的RCT未显示任一技术在死亡率、血流动力学或肾功能恢复方面有实际获益。
- 在缺乏一种KRT模式临床优越性证据时,选择不仅应基于临床结局,还应考虑资源与后勤。
- 需在新RCT中重新评估该问题,在结果出来前选择应主要基于各单位组织因素,在缺乏证据时不应否定任一模式。
研究设计与样本
- 本文为辩论类文章,讨论重症AKI患者选择间歇性HD还是CKRT应基于证据。
主要发现
- 比较间歇性HD与CKRT的RCT未显示任一技术在死亡率、血流动力学或肾功能恢复方面有实际获益。
- 这些RCT已超过15年,近期研究死亡率较既往研究更低。
- 这些RCT纳入相当比例可能无需KRT即可恢复的患者,已由近期多项研究显示。
- 健康技术评估与研究报告中关于间歇性HD与CKRT成本效果的结论异质且矛盾。
临床怎么用
- 在缺乏一种KRT模式临床优越性证据时,选择不仅应基于临床结局,还应考虑资源与后勤。
- 在新型RCT结果出来前,选择应主要基于各单位组织因素,在缺乏证据时不应否定任一模式。
局限性
- 比较间歇性HD与CKRT的RCT已超过15年。
- 这些RCT纳入相当比例可能无需KRT即可恢复的患者。
- 健康技术评估与研究报告中关于间歇性HD与CKRT成本效果的结论异质且矛盾。
- 需在新RCT中重新评估该问题,在结果出来前选择应主要基于各单位组织因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Kidney replacement therapy (KRT) plays a major role in the treatment of severe AKI. Intermittent hemodialysis (HD) and continuous KRT (CKRT) are the main modalities in critically ill patients with AKI. CKRT is the preferred modality in many countries because of its alleged superiority on both hemodynamic tolerance and on kidney function recovery. In fact, randomized controlled trials (RCTs) comparing the two modalities have not shown any actual benefit of one technique over the other on mortality, hemodynamics, or kidney function recovery. Those RCTs were conducted more than 15 years ago. Major progress was eventually made leading to much lower mortality rates in recent studies than in previous studies. In addition, those RCTs included a noticeable proportion of patients who could have recovered without ever receiving KRT, as demonstrated by several recent studies. In the absence of evidence of clinical superiority of one KRT modality, the choice must be addressed not only regarding clinical outcome but also resources and logistics. Conclusions of health technology assessments and study reports were heterogeneous and conflicting concerning cost-effectiveness of intermittent HD versus CKRT. All these considerations justify a reevaluation of the issue in new RCTs that take into account recent knowledge on KRT initiation and management. Pending results of such study, the choice should be guided mainly by organizational considerations in each unit and without condemning any modality in the absence of proof.
引用
- Chaïbi K, Dreyfuss D, Gaudry S, et al. Debate: Intermittent Hemodialysis versus Continuous Kidney Replacement Therapy in the Critically Ill Patient: The Choice Should Be Evidence Based. Clin J Am Soc Nephrol. 2023. PMID: 36723298. doi:10.2215/CJN.0000000000000104
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。